Syngene announced a significant extension of its long-standing collaboration with global biopharmaceutical leader Bristol Myers Squibb (BMS). The renewed strategic agreement will now continue through 2035, marking a new decade of deep partnership aimed at driving drug discovery, development, and commercialization.
Under the expanded deal, Syngene will broaden the scope of integrated services it delivers to BMS across the entire drug development lifecycle. These services span early-stage discovery functions including chemistry, biology, and drug metabolism through translational sciences, pharmaceutical development and manufacturing, clinical trial support, and data and information technology services. The aim is to enable a seamless progression of programs from concept to commercialization.
Peter Bains, Managing Director and CEO of Syngene International, said the extension reflects the deep scientific trust and operational synergy that has defined the relationship for over 25 years. He emphasized that the decade-long horizon will allow both companies to build new capabilities and infrastructure with strategic foresight, reinforcing Syngene’s role as a long-term partner in advancing innovative therapies.
Payal Sheth, Senior Vice President of Therapeutic Discovery Sciences at Bristol Myers Squibb, echoed the sentiment, noting that the collaboration is anchored in a shared commitment to patients. She highlighted that integrating Syngene’s scientific, development, and manufacturing strengths with BMS’s global research ambitions will help accelerate the delivery of transformative medicines to patients worldwide.
The partnership traces its roots back to 1998 and led to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D facility, commissioned in 2009. Today, this center houses around 700 Syngene scientists working as an extension of BMS’s global research team, contributing across therapeutic areas including cardiovascular disease, fibrosis, immunology, and oncology.
Over the years, BBRC has played a critical role in accelerating novel compounds from early discovery through preclinical milestones, reducing development timelines and costs. The extended collaboration underlines the partners’ shared vision to support future drug pipelines and strengthen Syngene’s position as a strategic, integrated scientific and manufacturing partner on the global stage.
